New combo therapy takes on tough myeloma
NCT ID NCT07093554
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a two-step treatment for people with multiple myeloma that has come back or stopped responding to other therapies. First, patients receive talquetamab, a drug that helps the immune system attack cancer cells. Then, they get an infusion of their own genetically modified immune cells (cilta-cel) to further fight the cancer. The study will enroll 31 participants and focus on whether this approach is safe and feasible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Talquetamab and ciltacabtagene autoleucel (cilta-cel)
What this could lead to
If successful, this combination approach could offer a new treatment option for patients with hard-to-treat multiple myeloma.
What could go wrong
This is a very early (phase 1b) and small study (31 people). The main goal is safety, not yet effectiveness. There are risks of serious side effects from both drugs, including immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert & the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact